PCSK9 inhibitors in the current management of atherosclerosis.


The history of proprotein convertase subtilisin/kexin type 9 (PCSK9) in medical science is fascinating and the evolution of knowledge of its function has resulted in new medications of major importance for the cardiovascular (CV) patient. PCSK9 functions as a negative control or feedback for the cell surface receptors for low-density lipoprotein including… (More)
DOI: 10.1016/j.acmx.2016.11.013